Actualizado 20/07/2009 11:02
- Comunicado -

Head-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanav

7 DAD Study Group, Friis-M0ller N, Reiss P, et al., Class of antiretroviral drugs and the risk of myocardial infarction, N Engl J Med, 2007;356(17):1723-35.

(Due to the length of the URL in reference 4, it may be necessary to copy and paste the hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

    
    Media Contact:
    Boehringer Ingelheim GmbH
    Corporate Division Communications
    Dr Heike Specht
    Binger Strasse 173
    55216 Ingelheim am Rhein
    Germany
    T: +49-6132-7793319
    E: press@boehringer-ingelheim.com
    Nick James
    T: +44-7776-258-990
    E: n.james@cca-uk.com

Media Contact: Boehringer Ingelheim GmbH, Corporate Division Communications, Dr Heike Specht, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, T: +49-6132-7793319, E: press@boehringer-ingelheim.com; Nick James, T: +44-7776-258-990, E: n.james@cca-uk.com